<DOC>
	<DOCNO>NCT01585155</DOCNO>
	<brief_summary>The purpose study evaluate efficacy TA-650 use Clinical activity index ( CAI ) score evaluation indicator pediatric patient moderate severe ulcerative colitis TA-650 administration dose 5 mg/kg week 0 , 2 , 6 , every 8 week week 14 22 . The safety pharmacokinetics also evaluate .</brief_summary>
	<brief_title>Clinical Study TA-650 Pediatric Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Patients diagnose ulcerative colitis least 3 month prior screen . Have active ulcerative colitis despite adequate conventional therapy . Patients severe pancolitis . Patients undergone surgery ulcerative colitis within 8 week enrollment judge require surgery ulcerative colitis enrollment . Patients history treatment infliximab biologic product ( antiTNFÎ± agent , antiIL6 agent , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Infliximab</keyword>
	<keyword>REMICADE</keyword>
	<keyword>TA-650</keyword>
</DOC>